France‐Hélène Joncas

Université Laval — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index401citations41works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Lipids, and Metabolism(14), Lipid metabolism and disorders(14), Prostate Cancer Treatment and Research(13), Lipoproteins and Cardiovascular Health(8), Hormonal and reproductive studies(8)

Publications41 total

Plasma ANGPTL3, Apo CIII, leptin, and lipid levels in patients with metastatic prostate cancer.
Journal of Clinical Oncology·2025
Lipid Profile, <scp>PCSK9</scp>, <scp>ANGPTL3</scp> and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer
Cancer Medicine·2025· 2 citedOpen Access
Correction: Circulating levels of PCSK9, ANGPTL3 and lp(a) in stage III breast cancers
BMC Cancer·2024Open Access
Abstract 5169: Circulating levels of ANGPTL3, PCSK9, apoCIII and lipoprotein (a) in high-grade serous ovarian cancer
Cancer Research·2024
Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary
Lipids in Health and Disease·2024· 3 citedOpen Access
Circulating levels of PCSK9, ANGPTL3, and other lipid-related factors in men with high-grade prostate cancer.
Journal of Clinical Oncology·2023
Levels of ANGPTL3 and characterization of other circulating cholesterol-related factors in high-grade serous ovarian cancers.
Journal of Clinical Oncology·2023
Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the PR.7 Trial
2023Open Access
Supplementary Figures 1-3, Supplementary Tables 1-5 from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the PR.7 Trial
2023Open Access
Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the PR.7 Trial
2023Open Access
Data from Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the PR.7 Trial
2023Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
BMC Cancer·2022· 26 citedOpen Access
Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translation
NAR Cancer·2022· 13 citedOpen Access
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
European Urology Open Science·2022· 23 citedOpen Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Research Square (Research Square)·2022Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
Journal of Clinical Oncology·2022
MP06-13 TARGETING THE ANDROGEN RECEPTOR AXIS TO IMPROVE RESPONSE TO BLADDER CANCER IMMUNOTHERAPY
The Journal of Urology·2022
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Research Square (Research Square)·2022Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Research Square (Research Square)·2022Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Research Square (Research Square)·2022· 3 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Paul Toren(14), Nabil G. Seidah(14), Frédéric Calon(14), Anne Gangloff(12), Yves Fradet(11), Emilie Wong Chong(9), Frédéric Pouliot(8), Chantal Guillemette(8), Keyue Ding(7), Alain Bergeron(6), Azik Hoffman(6), Éric Lévesque(6), Caroline Diorio(6), Caroline Diorio(5), Typhaine Gris(5), Véronique Turcotte(5), Patrick Caron(5), Laurence Klotz(5), Jonatan Blais(4), Pauline Adjibade(3)